Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A phase Ⅱ, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastroesophageal junction cancer: B-RAX trial (JACCRO GC-09).
Authors
Takahisa Suzuki
Department of Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan
Takahisa Suzuki , Naoki Izawa , Ryohei Kawabata , Kazuhiro Nishikawa , Masazumi Takahashi , Masato Nakamura , Atsushi Ishiguro , Hiroo Katsuya , Jun Hihara , Dai Manaka , Yuji Negoro , Mizutomo Azuma , Akihito Tsuji , Mitsugu Kochi , Takao Takahashi , Shigenori Kadowaki , Hirofumi Michimae , Yu Sunakawa , Wataru Ichikawa , Masashi Fujii
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
jRCTs031180061
DOI
10.1200/JCO.2022.40.4_suppl.306
Abstract #
306
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Efficacy and safety of nab-paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment for patients with advanced gastric cancer: A single institutional experience.
First Author: Mashiro Okunaka
Poster
2022 ASCO Annual Meeting
VOYAGER (KSCC1902): A single-arm, multicenter, phase II study of early induction of nivolumab during second-line treatment with taxane ± ramucirumab for advanced gastric or gastro-esophageal junction cancer.
First Author: Hiroo Katsuya
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT).
First Author: Kenro Hirata
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase II study of TAS-102 (FTD/TPI) in combination with ramucirumab (RAM) in advanced, refractory gastric (GC) or gastroesophageal junction (GEJ) adenocarcinomas (GEAs).
First Author: Rutika Mehta